EUVIMEDEUVIMED entdecken
Crossref

Clinically present mycobacterium tuberculosis RNA polymerase subunit RpoB K446 mutation confers broad-spectrum antibiotics resistance via pupylation

Qinglei Shen, Yu Huang, Fengmin Huo, Hongxiang Xu, Man Li, Lingxi Huang, Ying Xu, Peibo Li, Hairong Huang, Jianping Xie

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2025.109388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Qinglei Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Modern Biopharmaceuticals, School of Life Sciences, Southwest University, Chongqing, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, DNA-Directed RNA Polymerases, Antitubercular Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium tuberculosis (Mtb) infection remains a serious global public health threat due to its inherent and acquired resistance to clinical drugs. Meanwhile, the genomic sequences of many clinical isolates are informative to find novel drugs. Most drug-resistant mutations are clustered in the antibiotics-binding region of the targets, reducing affinity with antibiotics and diminishing the efficacy of antibiotics. However, the roles of mutations outside the drug-binding regions remain elusive. RNA polymerase encoded by rpoB is the primary target of the first-front antibiotics of rifampicin. Here, we found that many clinical isolates with RpoB K446 residue mutation, which does not directly interact with rifampicin, are susceptible to rifampicin. Further genetic experiments demonstrated that defective prokaryotic ubiquitin-like protein modification (pupylation) of the RpoBK446R mutant underlies the phenotypes, and chemically inhibition of the pup-proteasome system (PPS) pathway via repurposed drug bithionol or bortezomib can accelerate the killing of M. bovis BCG and Mtb by four clinical antibiotics with different mechanisms of action, namely RNA polymerase-targeting rifampicin (RIF), ribosome-targeting streptomycin (SM), gyrase-targeting moxifloxacin (MOX) and ATPase-targeting bedaquiline (BDQ). The data showed pupylation-proteasome pathway is target for broad-spectrum antibiotics or potentiators, and repurposed drugs bithionol or bortezomib can be further explored to be included in tuberculosis chemotherapy regimen to shorten the duration of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisDNA-Directed RNA PolymerasesAntitubercular AgentsDrug Resistance, BacterialBacterial ProteinsMicrobial Sensitivity TestsMutationHumansRifampinMolecular StructureDose-Response Relationship, DrugStructure-Activity Relationship

Stichwörter der Autor:innen

AntibioticsDrug repurposingMycobacterium tuberculosisPupylationRNA polymerase

Substanzen

DNA-Directed RNA PolymerasesAntitubercular AgentsrpoB protein, Mycobacterium tuberculosisBacterial ProteinsRifampin

Autor:innen und Institutionen

  • Institute of Modern Biopharmaceuticals, School of Life Sciences, Southwest University, Chongqing, China.
  • National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, China.
  • Chongqing Public Health Medical Center, Chongqing, China. Electronic address: 157318851@qq.com.
  • National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, China. Electronic address: nclhuang@ccmu.edu.cn.
  • Institute of Modern Biopharmaceuticals, School of Life Sciences, Southwest University, Chongqing, China. Electronic address: georgex@swu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shen, Q., Huang, Y., Huo, F., Xu, H., Li, M., Huang, L., Xu, Y., Li, P., Huang, H., & Xie, J. (2026). Clinically present mycobacterium tuberculosis RNA polymerase subunit RpoB K446 mutation confers broad-spectrum antibiotics resistance via pupylation. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109388

Vancouver

Shen Q, Huang Y, Huo F, Xu H, Li M, Huang L, et al. Clinically present mycobacterium tuberculosis RNA polymerase subunit RpoB K446 mutation confers broad-spectrum antibiotics resistance via pupylation. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2025.109388

BibTeX
@article{Shen2026,
  author = {Shen, Qinglei and Huang, Yu and Huo, Fengmin and Xu, Hongxiang and Li, Man and Huang, Lingxi and Xu, Ying and Li, Peibo and Huang, Hairong and Xie, Jianping},
  title = {Clinically present mycobacterium tuberculosis RNA polymerase subunit RpoB K446 mutation confers broad-spectrum antibiotics resistance via pupylation},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2025.109388}
}
Kostenlos starten →